Allogene Therapeutics Stock Forecast, Price & News

Allogene Therapeutics (NASDAQ:ALLO) Frequently Asked Questions

Is Allogene Therapeutics a buy right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Allogene Therapeutics stock.
View analyst ratings for Allogene Therapeutics or view top-rated stocks.

How has Allogene Therapeutics' stock been impacted by Coronavirus?

Allogene Therapeutics' stock was trading at $25.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALLO shares have decreased by 23.8% and is now trading at $19.09.
View which stocks have been most impacted by COVID-19.

Are investors shorting Allogene Therapeutics?

Allogene Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 5,670,000 shares, an increase of 19.6% from the October 31st total of 4,740,000 shares. Based on an average daily trading volume, of 1,840,000 shares, the days-to-cover ratio is presently 3.1 days. Approximately 8.5% of the shares of the stock are sold short.
View Allogene Therapeutics' Short Interest.

When is Allogene Therapeutics' next earnings date?

Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Allogene Therapeutics.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its earnings results on Thursday, November, 4th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by $0.01. The company had revenue of $0.05 million for the quarter. During the same quarter in the prior year, the business earned ($0.52) earnings per share.
View Allogene Therapeutics' earnings history.

What price target have analysts set for ALLO?

16 brokers have issued 12-month price objectives for Allogene Therapeutics' shares. Their forecasts range from $18.00 to $53.00. On average, they expect Allogene Therapeutics' stock price to reach $36.23 in the next year. This suggests a possible upside of 89.8% from the stock's current price.
View analysts' price targets for Allogene Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Allogene Therapeutics' key executives?

Allogene Therapeutics' management team includes the following people:

• David D. Chang, President, Chief Executive Officer & Director
• Eric Schmidt, Chief Financial Officer
• Barbra Sasu, Chief Scientific Officer
• Alison Moore, Chief Technical Officer
• Rafael G. Amado, Chief Medical Officer, EVP-Research & Development (LinkedIn Profile)

What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics CEO David Chang on Glassdoor.com. David Chang has an approval rating of 100% among Allogene Therapeutics' employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Allogene Therapeutics' key competitors?

Some companies that are related to Allogene Therapeutics include Neurocrine Biosciences (NBIX), Vir Biotechnology (VIR), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Exelixis (EXEL), Abcam (ABCM), Adagio Therapeutics (ADGI), Fate Therapeutics (FATE), Beam Therapeutics (BEAM), Halozyme Therapeutics (HALO), Kodiak Sciences (KOD), Twist Bioscience (TWST), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT) and SpringWorks Therapeutics (SWTX).
View all of ALLO's competitors.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO.

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.11%), Primecap Management Co. CA (2.53%), Alliancebernstein L.P. (2.26%), Casdin Capital LLC (1.47%), Goldman Sachs Group Inc. (1.39%) and Geode Capital Management LLC (0.88%). Company insiders that own Allogene Therapeutics stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Owen N Witte, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends for Allogene Therapeutics.

Which major investors are selling Allogene Therapeutics stock?

ALLO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Citigroup Inc., Morgan Stanley, Schonfeld Strategic Advisors LLC, Barclays PLC, Victory Capital Management Inc., Caption Management LLC, and Deutsche Bank AG. Company insiders that have sold Allogene Therapeutics company stock in the last year include Eric Thomas Schmidt, Owen N Witte, Rafael Amado, and Veer Bhavnagri.
View insider buying and selling activity for Allogene Therapeutics or view top insider-selling stocks.

Which major investors are buying Allogene Therapeutics stock?

ALLO stock was purchased by a variety of institutional investors in the last quarter, including Casdin Capital LLC, Dimensional Fund Advisors LP, Nordea Investment Management AB, Goldman Sachs Group Inc., BlackRock Inc., Pier Capital LLC, Lombard Odier Asset Management Switzerland SA, and UBS Group AG.
View insider buying and selling activity for Allogene Therapeutics or or view top insider-buying stocks.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $19.09.

How much money does Allogene Therapeutics make?

Allogene Therapeutics has a market capitalization of $2.72 billion. The company earns $-250.22 million in net income (profit) each year or ($1.88) on an earnings per share basis.

How many employees does Allogene Therapeutics have?

Allogene Therapeutics employs 265 workers across the globe.

What is Allogene Therapeutics' official website?

The official website for Allogene Therapeutics is www.allogene.com.

Where are Allogene Therapeutics' headquarters?

Allogene Therapeutics is headquartered at 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 457-2700 or via email at [email protected].